

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Gladwin *et al.*

**Application No.** 10/563,683

**Filed:** October 4, 2006

**Confirmation No.** 3225

**For:** USE OF NITRITE SALTS FOR THE  
TREATMENT OF CARDIOVASCULAR  
CONDITIONS

**FILED VIA EFS**

**Examiner:** Anna Pagonakis

**Art Unit:** 1614

**Attorney Reference No.** 4239-67618-07

FILED VIA ELECTRONIC FILING SYSTEM  
COMMISSIONER FOR PATENTS

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(4)**

Listed on the accompanying form PTO-1449 are four English-language documents, three of which are submitted herewith. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement (IDS) before the mailing of a first Office action after the filing of a request for continued examination. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301  
cc: Docketing

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630